New centre for AFC
SK Pharmteco affiliate Ampac Fine Chemicals (AFC) has added a complex molecule chemistry and engineering centre at its main site in Rancho Cordova, California. “This expands upon our core technologies such as energetic chemistry, high potency, chromatography and continuous processing”, said Dr John Jacobsen, executive director of R&D.
Designed to address the demand for more complex syntheses, which often rely on multi-step telescoped transformations, the centre will support the development of such complex molecules as custom phosphoramidites, UV-sensitive compounds and pegylated substrates, from grams to kilos. It also has analytical testing capabilities.
RELATED ARTICLES
Two CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
CatSci has opened a second oligonucleotides laboratory, which it will use “to introduce novel workflows for the rapid production of vast numbers of oligos at a scale optimised for rapid screening”.
Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”.
